Follow Us on Google
By Zubaida Baba Ibrahim
Scientist Sarah Oladejo, is advancing a new paradigm in cancer drug discovery by integrating machine learning, large-scale transcriptomics, and natural-compound pharmacology.
In a recent study published in Bioinformatics Advances, Scientist Oladejo and her colleagues identified carnosol, a bioactive compound derived from Coffea arabica (coffee), as a promising inhibitor of matrix metalloproteinase-7 (MMP7)—a gene now strongly linked to poor clinical outcomes in cervical cancer.
The research has since led to a federally granted patent by the Federal Republic of Nigeria, recognizing an invention titled “Tailored Computational Identification of MMP7 Natural Compounds from Coffea arabica for Cervical Cancer Treatment.” The patent underscores the originality and translational relevance of the work, marking a critical step toward therapeutic development.
Scientist Oladejo emphasized that the project was driven by an urgent global health need. “Cervical cancer continues to impose a disproportionate burden, particularly in regions where treatment options are limited and resistance to therapy is common,” she said. “We wanted to identify new, biologically grounded strategies that could be both effective and broadly accessible.”
She explained that coffee offered a unique and underexplored opportunity. “Coffee is one of the most widely consumed substances in the world and contains a diverse repertoire of bioactive compounds,” Scientist Oladejo noted. “Yet its relevance to cervical cancer–specific molecular drivers had not been systematically examined. We saw an opportunity to connect a familiar natural product to a clinically meaningful cancer target using computational biology.”
A central contribution of the study is the identification of MMP7 as an independent predictor of poor survival in cervical cancer. By analyzing transcriptomic data from more than 300 cervical cancer tumors, Scientist Oladejo and her colleagues demonstrated that elevated MMP7 expression consistently correlates with adverse clinical outcomes.
“This finding elevates MMP7 from a general cancer-associated gene to a clinically relevant therapeutic target in cervical cancer,” she explained. “It provides a clear molecular focal point for precision drug discovery.”
After prioritizing MMP7, the researchers applied machine-learning–based pharmacological modeling to identify compounds with high inhibitory potential. Scientist Oladejo noted that they trained a Random-Forest regression model using hundreds of experimentally validated MMP7 inhibitors before screening coffee-derived compounds against this framework.
“Carnosol emerged as a top-ranking candidate with strong predicted activity against MMP7,” she said. “What makes this approach powerful is that it is not anecdotal—it is grounded in data integration, statistical rigor, and predictive modeling.”
The subsequent patent, Scientist Oladejo explained, represents more than academic recognition. “The patent formally validates the originality, novelty, and translational potential of our computational framework,” she said. “It shows that computational biology can generate protectable intellectual property with real therapeutic promise.”
Beyond cervical cancer, Scientist Oladejo believes the study introduces a scalable strategy for natural-compound discovery. “This framework can be applied to other cancers and diseases,” she noted. “It opens new possibilities for identifying low-toxicity, target-specific therapeutics guided by molecular relevance rather than trial-and-error screening.”
Reflecting on her broader research philosophy, Scientist Oladejo described her work as fundamentally translational. “Computational tools allow us to interrogate biology at a scale that was previously impossible,” she said. “But the goal is always to connect those insights to patient outcomes.” Growing up in Nigeria, she added, shaped that perspective. “Seeing how cancer and chronic diseases affect families and communities continues to drive my commitment to rigorous, impact-driven science.”
Looking ahead, Scientist Oladejo emphasized that the groundwork for therapeutic development is now firmly established. “We have identified the molecular target, the candidate compound, and the computational rationale linking them,” she said. “The next step is experimental validation, with the long-term goal of contributing to more effective and accessible treatments for cervical cancer.”
“At its core,” Scientist Oladejo concluded, “this work shows that meaningful innovation can emerge from re-examining familiar substances through advanced computational lenses—even something as everyday as coffee.”
